You are here

Development of a long-acting, injectable controlled release butyrylcholinesterase formulation using predictive modeling.

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-13-P-0169
Agency Tracking Number: C131-107-0040
Amount: $99,575.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD13-107
Solicitation Number: 2013.1
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): 2013-05-01
Award End Date (Contract End Date): 2013-10-31
Small Business Information
4551 Forbes Ave Ste. 301
Pittsburgh, PA -
United States
DUNS: 055292329
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Sam Rothstein
 Chief Scientific Officer
 (412) 709-1659
Business Contact
 Larry Zana
Title: Chief Executive Officer
Phone: (412) 213-8788
Research Institution

Elevated levels of human butyrylcholinesterase (BuChE) confer protection from chemical warfare nerve agents and other organophosphorous chemicals. As a prophylactic, the key to enabling this protection is the ability to maintain elevated concentrations of BuChE in the plasma for days or weeks. Thus far, plasma-derived and PEGylated recombinant forms of BuChE have been tested in humans. However, both have fallen short of providing cost-effective protection in scenarios where repeated intravenous administration by a health care worker is impractical. Qrono proposes to meet the need for an organophosphorous prophylaxis with custom developed, injectable microparticles that will sustain BuChE delivery for 10 days. In Phase I, Qrono will optimize the design of BuChE containing microparticles using its proprietary formulation design software, test their in vitro release and simulate their pharmacokinetics for animal models and humans. Qrono"s unique computational approach to formulation development provides greater efficiency and accuracy in the design of depot medications than the industry standard experiment-driven methods. In Phases II and III Qrono will test the pharmacokinetics and prophylactic capabilities of its BuChE formulation with nerve agent challenge studies in animal models and then pursue commercialization through clinical trials.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government